FORT WORTH, Texas, June 22, 2011 /PRNewswire/ -- Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader in advanced wound care solutions today announced that Company President Deborah Jenkins Hutchinson, will present a corporate update at the 6th annual OneMedForum NY Conference on Thursday, June 23, 2011 at 10 am EDT held at The Roosevelt Hotel on 45 East 45 St. in New York City. The presentation will be webcast live at OneMedPlace.com: http://www.onemedplace.com/forum/livewebcast
Deborah will be accompanied by WNDM CEO Scott Haire as they address the following topics:
OneMedForum NY 2011 Conference is a gathering of fast growing, emerging healthcare and life science companies in Europe and North America. This will be the 6th OneMedForum and will focus on critical success factors for building companies on both sides of the Atlantic. Leading European venture and strategic investors have played an active role in helping the event attract the most promising companies and leading investors from Europe and the United States.
More information and access to the webcast can be found on the Conference's website, http://www.onemedplace.com/forum/, or under the Upcoming Events tab on http://www.wmgtech.com. Lastly, the presentation webcast will be linked and viewable on wmgtech.com in "Investor Presentations", under the Investor Relations tab.
Founded in 2008, OneMedForum events are held biannually in San Francisco in January and in New York in June. They are designed to create a communications platform for emerging companies to connect with strategic partners and investors. OneMedForum NY was launched in 2010 which successfully brought together 74 promising private and microcap healthcare and life science companies with a wide range of investors and strategic partners.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com and http://www.celleraterx.com.
Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com
|SOURCE Wound Management Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved